$CVM News

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

CEL-SCI Announces Closing of Offering

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi Arabia

CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month

CEL-SCI Corporation Announces Pricing of Offering

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

CEL‑SCI To Sign Saudi Amarox Deal At BIO International Convention 2026, Advancing Multikine Commercialization In Saudi Arabia

CEL-SCI Reports Fiscal Second Quarter 2026 Results

CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoY

CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

CEL-SCI Signs Strategic Partnership, Distribution, And Revenue Sharing Agreement With Amarox For Regulatory Affairs, Marketing And Potential Commercialization Of Multikine In Treatment Of Head And Neck Cancer In Saudi Arabia

CEL-SCI Reports Fiscal First Quarter 2026 Results

CEL-SCI Q4 2025 EPS $(0.68) Vs $(3.25) Q4 2024

Cel-Sci: Fiscal Q1 Earnings Snapshot

CEL-SCI Reports Fiscal 2025 Results

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference